Top

Published in:

01-08-2018 | PRECLINICAL STUDIES

Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation

Authors: Hsiu-Yu Liu, Andrea Z. Tuckett, Myles Fennell, Ralph Garippa, Johannes L. Zakrzewski

Published in: Investigational New Drugs | Issue 4/2018

Summary

Oxidative stress and cellular response mechanisms such as NRF2-mediated antioxidant responses play differential roles in healthy and diseased cells. Constant generation and elimination of high levels of reactive oxygen species is a hallmark of many cancer cell types; this phenomenon is not observed during steady state of healthy cells. Manipulation of NRF2 transcriptional activity and the cellular redox homeostasis therefore has potential to be therapeutically exploitable for cancer therapy by preferentially targeting cancer cells for induction of oxidative stress. We found that the NRF2 inhibitor brusatol triggered increased oxidative stress while compromising viability and proliferation of multiple myeloma cells. Using a repurposing approach we discovered that the Cdc7/CDK9 inhibitor PHA-767491 is also a potent inhibitor of NRF2 transcriptional activity. The molecule was identified by high throughput screening of a library of about 5900 drug-like molecules. Screening assays included two cell-based assays using HepG2 hepatocellular carcinoma cells: a) A NRF2 nuclear translocation assay, and b) A NRF2 luciferase reporter assay. Validation assays were performed in multiple myeloma cells and included detection of mitochondrial superoxide levels and MTS assays. We found that PHA-767491 treatment of multiple myeloma cells was associated with inhibition of nuclear translocation of NRF2, increased mitochondrial superoxide levels and inhibition of cell growth. Our findings suggest that PHA-767491 is a promising drug candidate for cancer therapy with NRF2 inhibitory potency contributing to its anti-cancer properties.

Available only for authorised users

Lee JM, Johnson JA (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37:139–143PubMed

Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931–947. https://doi.org/10.1038/nrd4002 CrossRefPubMed

Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579–591. https://doi.org/10.1038/nrd2803 CrossRefPubMed

Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374:337–348. https://doi.org/10.1042/bj20030754 CrossRefPubMedPubMedCentral

Rushmore TH, Morton MR, Pickett CB (1991) The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266:11632–11639PubMed

He X, Ma Q (2009) NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation. Mol Pharmacol 76:1265–1278. https://doi.org/10.1124/mol.109.058453 CrossRefPubMedPubMedCentral

Imhoff BR, Hansen JM (2010) Tert-butylhydroquinone induces mitochondrial oxidative stress causing Nrf2 activation. Cell Biol Toxicol 26:541–551. https://doi.org/10.1007/s10565-010-9162-6 CrossRefPubMed

Gharavi N, Haggarty S, El-Kadi AO (2007) Chemoprotective and carcinogenic effects of tert-butylhydroquinone and its metabolites. Curr Drug Metab 8:1–7CrossRefPubMed

Muller M (2002) Pyocyanin induces oxidative stress in human endothelial cells and modulates the glutathione redox cycle. Free Radic Biol Med 33:1527–1533CrossRefPubMed

10.

Liu K, Wang X, Sha K, Zhang F, Xiong F, Wang X, Chen J, Li J, Churilov LP, Chen S, Wang Y, Huang N (2017) Nuclear protein HMGN2 attenuates pyocyanin-induced oxidative stress via Nrf2 signaling and inhibits Pseudomonas aeruginosa internalization in A549 cells. Free Radic Biol Med 108:404–417. https://doi.org/10.1016/j.freeradbiomed.2017.04.007 CrossRefPubMed

11.

Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R (2008) Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol 141:494–503. https://doi.org/10.1111/j.1365-2141.2008.07066.x CrossRefPubMed

12.

Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H, Unlu M (2008) High levels of oxidative stress in patients with advanced lung cancer. Respirology (Carlton, Vic) 13:112–116. https://doi.org/10.1111/j.1440-1843.2007.01212.x CrossRef

13.

Moloney JN, Cotter TG (2017) ROS signalling in the biology of cancer. Semin Cell Dev Biol. https://doi.org/10.1016/j.semcdb.2017.05.023

14.

Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1:45–49. https://doi.org/10.1016/j.redox.2012.10.001 CrossRefPubMedPubMedCentral

15.

Chio II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Ohlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, Tuveson DA (2016) NRF2 Promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166:963–976. https://doi.org/10.1016/j.cell.2016.06.056 CrossRefPubMedPubMedCentral

16.

Syu JP, Chi JT, Kung HN (2016) Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget 7:14659–14672. https://doi.org/10.18632/oncotarget.7406 PubMedPubMedCentralCrossRef

17.

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, KH Y, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106–109. https://doi.org/10.1038/nature10189 CrossRefPubMedPubMedCentral

18.

Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66–76. https://doi.org/10.1016/j.taap.2009.08.028 CrossRefPubMed

19.

Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:1235–1243. https://doi.org/10.1093/carcin/bgn095 CrossRefPubMedPubMedCentral

20.

Jaramillo MC, Zhang DD (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27:2179–2191. https://doi.org/10.1101/gad.225680.113 CrossRefPubMedPubMedCentral

21.

Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD (2014) Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 74:7430–7441. https://doi.org/10.1158/0008-5472.can-14-1439 CrossRefPubMedPubMedCentral

22.

No JH, Kim YB, Song YS (2014) Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev 19:111–117. https://doi.org/10.15430/jcp.2014.19.2.111 CrossRefPubMedPubMedCentral

23.

Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 108:1433–1438. https://doi.org/10.1073/pnas.1014275108 CrossRefPubMedPubMedCentral

24.

Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AF, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldring CE, Park BK (2015) Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med 78:202–212. https://doi.org/10.1016/j.freeradbiomed.2014.11.003 CrossRefPubMedPubMedCentral

25.

Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, Schreiber S, Schafer H (2013) Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32:4825–4835. https://doi.org/10.1038/onc.2012.493 CrossRefPubMed

26.

Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24:167–175. https://doi.org/10.1038/nbt1186 CrossRefPubMed

27.

Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1:a001651. https://doi.org/10.1101/cshperspect.a001651 CrossRefPubMedPubMedCentral

28.

Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sanchez-Perez P, Cadenas S, Lamas S (2015) Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol 6:183–197. https://doi.org/10.1016/j.redox.2015.07.008 CrossRefPubMedPubMedCentral

29.

DiDonato JA, Mercurio F, Karin M (2012) NF-kappaB and the link between inflammation and cancer. Immunol Rev 246:379–400. https://doi.org/10.1111/j.1600-065X.2012.01099.x CrossRefPubMed

30.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647. https://doi.org/10.1074/jbc.M200360200 CrossRefPubMed

31.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA (2007) Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 11:1587–1609. https://doi.org/10.1517/14728222.11.12.1587 CrossRefPubMedPubMedCentral

32.

Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C (2008) A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4:357–365. https://doi.org/10.1038/nchembio.90 CrossRefPubMed

33.

Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C (2011) Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther 10:1624–1634. https://doi.org/10.1158/1535-7163.mct-10-1119 CrossRefPubMed

34.

Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, Feuerstein GZ (2003) Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 304:172–178. https://doi.org/10.1124/jpet.102.040246 CrossRefPubMed

35.

Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, Doerge DR, Helferich WG, Hergenrother PJ (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2:543–550. https://doi.org/10.1038/nchembio814 CrossRefPubMed

36.

Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2:474–479. https://doi.org/10.1038/nchembio809 CrossRefPubMed

37.

Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21:103–115. https://doi.org/10.1038/cr.2010.178 CrossRefPubMed

38.

Bubici C, Papa S, Dean K, Franzoso G (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25:6731–6748. https://doi.org/10.1038/sj.onc.1209936 CrossRefPubMed

39.

DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC (2015) NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 47:1475–1481. https://doi.org/10.1038/ng.3421 CrossRefPubMedPubMedCentral

40.

Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G (2014) Serine and glycine metabolism in cancer. Trends Biochem Sci 39:191–198. https://doi.org/10.1016/j.tibs.2014.02.004 CrossRefPubMedPubMedCentral

41.

Shono Y, Tuckett AZ, Liou HC, Doubrovina E, Derenzini E, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL (2016) Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-kappaB-controlled oxidative stress responses. Cancer Res 76:377–389. https://doi.org/10.1158/0008-5472.can-14-2814 CrossRefPubMedPubMedCentral

Title: Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation
Authors: Hsiu-Yu Liu
Andrea Z. Tuckett
Myles Fennell
Ralph Garippa
Johannes L. Zakrzewski
Publication date: 01-08-2018
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0557-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer